naxagolide has been researched along with carbidopa in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (57.14) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ahlskog, JE; Bailey, PA; Miller, PM; Muenter, MD | 1 |
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ; Tye, S | 1 |
Cedarbaum, JM; Clark, M; Green-Parsons, A; Toy, LH | 1 |
Factor, SA; Sanchez-Ramos, JR; Weiner, WJ | 1 |
Barter, R; Koller, WC; Vetere-Overfield, B | 1 |
Baumann, G; Chin, L; Lieberman, A | 1 |
Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM | 1 |
1 trial(s) available for naxagolide and carbidopa
Article | Year |
---|---|
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxazines; Parkinson Disease | 1991 |
6 other study(ies) available for naxagolide and carbidopa
Article | Year |
---|---|
Modulatory role for CCK-B antagonists in Parkinson's disease.
Topics: Animals; Benzodiazepinones; Carbidopa; Cholecystokinin; Devazepide; Dopamine Agents; Levodopa; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenylurea Compounds; Receptors, Cholecystokinin; Saimiri | 1990 |
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Topics: Activities of Daily Living; Antiparkinson Agents; Brain; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Oxazines; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2 | 1990 |
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease | 1989 |
Tremors in early Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Tremor | 1989 |
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Humans; Hypromellose Derivatives; Lactose; Levodopa; Lisuride; Methylcellulose; Middle Aged; Nausea; Oxazines; Parkinson Disease; Pergolide; Psychomotor Performance; Receptors, Dopamine | 1988 |
Antiparkinsonian activity of a single oral dose of PHNO.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time | 1987 |